Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion. Rznomics will ...

Eli Lilly has a lot going for it ... Lilly was also working on something else in the background. As Novo Nordisk did, Lilly developed an alternative version of its diabetes drug -- Zepbound ...

Eli Lilly & Co. said Tuesday it’s cutting ... as there were shortages and a high patient need. Against that background, Lilly ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...

This background helps highlight how important Eli Lilly's most recent brand-new approval is. The company earned the thumbs-up from the U.S. Food and Drug Administration (FDA) for Kisunla ...

th { background-color: #293a5a ... Through a meticulous analysis of Eli Lilly, we can observe the following trends: Notably, the current Price to Earnings ratio for this stock, 117.51, is 4.37x ...

Eli Lilly's weight loss treatment Zepbound might ... along with Senator Bernie Sanders. As a background, the company has seen a significant jump in operating margin recently.